| 0 (0%) | 11-11 15:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 54.18 | 1-year : | 63.28 |
| Resists | First : | 46.38 | Second : | 54.18 |
| Pivot price | 38.18 |
|||
| Supports | First : | 38.23 | Second : | 33.2 |
| MAs | MA(5) : | 42.93 |
MA(20) : | 37.59 |
| MA(100) : | 31 |
MA(250) : | 33.69 |
|
| MACD | MACD : | 2.1 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 66.1 |
D(3) : | 67.2  |
| RSI | RSI(14): 66.5 |
|||
| 52-week | High : | 47.31 | Low : | 22.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VCYT ] has closed below upper band by 16.4%. Bollinger Bands are 196% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 43.32 - 43.49 | 43.49 - 43.66 |
| Low: | 41.3 - 41.49 | 41.49 - 41.67 |
| Close: | 42.04 - 42.34 | 42.34 - 42.63 |
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Tue, 11 Nov 2025
Veracyte (VCYT): Exploring Valuation After Recent Share Price Rally - simplywall.st
Tue, 11 Nov 2025
Morgan Stanley Adjusts Price Target for VCYT to $40 | VCYT Stock News - GuruFocus
Tue, 11 Nov 2025
VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up - Zacks Investment Research
Mon, 10 Nov 2025
Is VCYT stock near bottom after decline - Weekly Trend Report & Risk Adjusted Swing Trade Ideas - newser.com
Mon, 10 Nov 2025
Will VCYT stock recover after recent drop - Earnings Growth Summary & Entry Point Strategy Guides - newser.com
Sun, 09 Nov 2025
Can VCYT stock beat analyst upgrades - Weekly Loss Report & Fast Exit and Entry Trade Guides - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 79 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 109.2 (%) |
| Shares Short | 6,720 (K) |
| Shares Short P.Month | 9,130 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.52 |
| Profit Margin | 5.5 % |
| Operating Margin | 10.9 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | 2.2 % |
| Qtrly Rev. Growth | 13.8 % |
| Gross Profit (p.s.) | 4.29 |
| Sales Per Share | 6.09 |
| EBITDA (p.s.) | 0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 93 (M) |
| Levered Free Cash Flow | 75 (M) |
| PE Ratio | 126.23 |
| PEG Ratio | 0 |
| Price to Book value | 2.76 |
| Price to Sales | 7.04 |
| Price to Cash Flow | 36.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|